July 25, 2025Frontiers in ImmunologyOpen Access

Emerging IO checkpoints in gastrointestinal oncology

View Full Paper

Ask AI

Bookmark

Authors

ATAlireza TojjariUPMC Hillman Cancer Center ASAnwaar SaeedUniversity of Pittsburgh Medical Center LCLudimila CavalcanteUniversity of Virginia Cancer Center

Discussion

Member takes

Implication

This review highlights immune checkpoints like TIGIT and GITR that enhance T cell responses in gastrointestinal oncology, suggesting new treatment possibilities.

Key Points

Immune checkpoints such as TIGIT and GITR are changing therapeutic strategies in gastrointestinal oncology.
Research shows that VISTA and STING pathways enhance the body's anti-tumor response, offering new avenues for treatment.
TIM-3 is associated with T cell fatigue and represents a potential target against immune evasion in tumors.
Combining immune checkpoint therapies with traditional treatments could improve patient outcomes in GI cancers.

Cite This Study

Tojjari et al. (2025) studied this question.

synapsesocial.com/papers/689a0627e6551bb0af8ce27b https://doi.org/10.3389/fimmu.2025.1575713

View Full Paper

Ask AI

Bookmark

Implication

This review highlights immune checkpoints like TIGIT and GITR that enhance T cell responses in gastrointestinal oncology, suggesting new treatment possibilities.

Emerging IO checkpoints in gastrointestinal oncology

Discussion

Member takes

Implication

Key Points

Cite This Study

Emerging IO checkpoints in gastrointestinal oncology

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider